Trials / Completed
CompletedNCT00041652
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
A Phase I/II Clinical Trial of Immunotherapy With Humanized MN-14 IgG in Recurrent, Metastatic, Unresectable Colorectal and Breast Carcinomas
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.
Conditions
- Colorectal Cancer
- Colon Cancer
- Rectal Cancer
- Colorectal Neoplasms
- Colorectal Carcinoma
- Breast Cancer
- Breast Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hMN14 (labetuzumab) |
Timeline
- Start date
- 2000-02-01
- Completion
- 2003-06-01
- First posted
- 2002-07-15
- Last updated
- 2021-08-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00041652. Inclusion in this directory is not an endorsement.